Synergism Between IL21 and Anti-PD-1 Combination Therapy is Underpinned by the Coordinated Reprogramming of the Immune Cellular Network in the Tumor Microenvironment

T cell–stimulating cytokines and immune checkpoint inhibitors (ICI) are an ideal combination for increasing response rates of cancer immunotherapy. However, the results of clinical trials have not been satisfying. It is important to understand the mechanism of synergy between these two therapeutic m...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Shaoxian, Huang, Hao, Sun, Runzi, Gao, David Shihong, Ye, Fan, Huang, Jianing, Li, Ella, Ni, Andrew, Lu, Kevin GuoKai, Chen, Kong, Jiang, Jingting, Morel, Penelope A., Zhong, Ziyang, Lu, Binfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402650/
https://www.ncbi.nlm.nih.gov/pubmed/37546701
http://dx.doi.org/10.1158/2767-9764.CRC-23-0012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402650/
https://www.ncbi.nlm.nih.gov/pubmed/37546701
http://dx.doi.org/10.1158/2767-9764.CRC-23-0012

Ejemplares similares